| ID | 119128 |
| 著者 |
Okada, M
Sakamoto Hospital
Iwatsuki, N
Sakamoto Hospital
Sakamoto, K
Sakamoto Hospital
Ogawa, T
Sakamoto Hospital
|
| キーワード | imeglimin (Twymeeg)
type 2 diabetes (T2D)
Trials of Imeglimin for Efficacy and Safety (TIMES)
oral hypoglycemic agent (OHA)
Metformin
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Background: Imeglimin (Twymeeg) is latest focus of oral hypoglycemic agent (OHA).
Case presentation: Current case is 69-year-old male with type 2 diabetes (T2D) for 18 years. Result: HbA1c value increased to 7.6% in Sept 2022, and then metformin 750mg/day was changed to imeglimin 2000mg/day. HbA1c decreased to 6.9% for 4 months. Discussion and conclusion: Large study of Trials of IMeglimin for Efficacy and Safety (TIMES) showed beneficial efficacy for combined treatment of OHAs. Imeglimin has dual effects increasing insulin secretion and reducing insulin resistance. Perspectives concerning pharmacological effects of metformin and imeglimin are described in diabetic practice and research. |
| 掲載誌名 |
International Journal of Endocrinology and Diabetes
|
| ISSN | 26943875
|
| 出版者 | Pubtexto Publishers
|
| 巻 | 6
|
| 号 | 1
|
| 開始ページ | 145
|
| 発行日 | 2023-02-05
|
| 権利情報 | This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
|
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
